Table 3.

Univariate and Multivariate Analyses for Overall Survival in the Propensity Score-matched Cohort.

				Univariate analysis						Multivariate analysis
				HR		95% CI		p value		HR		95% CI		p value
Age, years		≥65		0.951		0.673-1.343		0.775
Sex		Male		1.497		0.924-2.426		0.102
ECOG performance status		1-2		1.473		1.067-2.034		0.019		1.414		1.012-1.976		0.042
Tumor location		Pancreas body-tail		1.332		0.958-1.853		0.088
Tumor size, mm		≥30		1.128		0.801-1.588		0.490
Stage		UR-M		1.848		1.307-2.612		0.001		1.807		1.111-2.942		0.017
Metastatic sites		Lung Liver Peritoneum		0.813 1.928 0.961		0.420-1.574 1.377-2.699 0.608-1.521		0.540 0.000 0.866		1.103		0.688-1.769		0.683
Number of metastatic sites		≥3		3.587		1.032-12.467		0.044		3.355		0.931-12.084		0.064
CRP/Alb		≥0.18		1.296		0.936-1.795		0.119
NLR		≥5		1.299		0.860-1.961		0.213
PLR		≥150		0.921		0.667-1.272		0.618
m-GPS		1-2		2.816		1.968-4.029		0.000		2.698		1.855-3.923		0.000
PNI		≥45		0.936		0.679-1.291		0.688
CEA, ng/mL		≥5		1.368		0.989-1.891		0.058
CA19-9, UI/mL		≥37		1.217		0.798-1.858		0.362
BMI, kg/m2		≥25		0.394		0.192-0.809		0.011		0.499		0.232-1.074		0.075
Sarcopenia		Yes		0.935		0.680-1.286		0.680

HR: hazard ratio, CI: confidence interval, CRP: C-reactive protein, NLR: neutrophil/lymphocyte ratio, PLR: platelet/lymphocyte ratio, m-GPS: modified Glasgow prognostic score, PNI: prognostic nutritional index, CA19-9: carbohydrate antigen 19-9, CEA: carcinoembryonic antigen, BMI: body mass index, SMI: skeletal muscle index